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Background: Dupuytren’s disease (DD) is a slow, progressive fibroproliferative disorder affecting the palms of the
hands. The disease is characterized by the formation of collagen rich- cords which gradually shorten by the action
of myofibroblasts resulting in finger contractures. It is a disease that is confined to humans, and a major limiting
factor in investigating this disorder has been the lack of a faithful animal model that can recapitulate its distinct
biology. The aim of this study was to develop such a model by determining if Dupuytren’s disease (DD)- and control
carpal tunnel (CT)-derived fibroblasts could survive in the forepaw of the nude rats and continue to exhibit the distinct
characteristics they display in in vitro cultures.
Methods: 1x107 fluorescently labeled DD- and CT-derived fibroblasts were transplanted into the left and right
forepaws of nude rats respectively. Cells were tracked at regular intervals for a period of two months by quantifying
emitted fluorescent signal using an IVIS imaging system. After a period of 62 days rat forepaw connective tissues were
harvested for histology and total RNA was isolated. Human-specific probes were used to perform real time
RT-PCR assays to examine the expression patterns of gene products associated with fibrosis in DD. Rat forepaw skin
was also harvested to serve as an internal control.
Results: Both CT- and DD-derived fibroblasts survived for a period of 62 days, but DD-derived cells showed a significantly
greater level of persistent fluorescent signal at the end of this time than did CT-derived cells. mRNA expression levels of
α-smooth muscle actin (α-SMA), type I- and type III- collagens were all significantly elevated in the forepaw receiving DD
cord-derived fibroblasts in comparison to CT-derived fibroblasts. Masson’s trichrome stain confirmed increased collagen
deposition in the forepaw that was injected with DD cord-derived fibroblasts.
Conclusions: For the first time we describe an animal model for Dupuytren’s disease at the orthotopic anatomical
location. We further show that gene expression differences between control (CT) and diseased (DD) derived fibroblasts
persist when these cells are transplanted to the forepaw of the nude rat. These preliminary findings indicate that, with
further refinements, this animal model holds promise as a baseline for investigating novel therapeutic regimens to
determine an effective strategy in treating DD.
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Dupuytren’s disease (DD) is a complex, progressive,
fibroproliferative disorder which commonly affects
populations of northern European descent and has a
prevalence of >7 % in the United States [1]. DD affects
the palmar fascia of the hand resulting in digital flexion
contractures. DD is considered a benign, heritable fibrosis
[2] inherited in an autosomal dominant fashion with vari-
able penetrance [3].
Dupuytren’s disease generally begins as a hard nodule
on the palm and slowly progresses into a fibrous cord
that pulls the affected digit into a flexed contracted
position [4, 5]. The digits most commonly affected are
the ring and small fingers, and contractures usually
occur at either the metacarpophalangeal (MP) joint,
proximal interphalangeal (PIP) joint, or rarely the distal
interphalangeal joint. The nodule is a relatively vascular
tissue containing a dense population of fibroblasts, with
a high proportion being myofibroblasts [6, 7], specialized
cells that express α-smooth muscle actin (α-SMA) [8]
and are the likely effectors of the tissue contraction
characteristic of DD. The nodule may develop into a
collagen-rich fibrotic cord as the disease progresses over
time, with a persistent abundance of myofibroblasts.
Recent studies show that cells derived from primary
nodule and cord have similar gene expression profiles
[9], indicating that both nodule- and cord-derived fibro-
blasts are appropriate subjects of study in examining the
progression of DD.
The exact etiopathogenesis of DD remains unknown.
In addition to a genetic predisposition, environmental and
behavioral factors (eg. alcohol consumption and manual
labor) [10, 11] have also been implicated in DD, as have
certain co-morbid conditions (eg. diabetes, epilepsy and
hypercholesterolemia) [12–14]. At a more basic level, DD is
marked by a disturbance in collagen metabolism, and by
changes in other extracellular matrix protein levels,
including fibronectin [15] and periostin [16]. Dolmans
et al. (2011) [17] identified nine different loci involved
in genetic susceptibility to DD of which six are in the
vicinity of genes encoding proteins in the Wnt-
signaling pathway, suggesting that malfunctioning of
this pathway may be a key factor for the progression
and/or recurrence of DD. But the most important
factor linked to progression of DD remains the prolifer-
ation of fibroblasts and their transformation to a myofi-
broblast phenotype, as evidenced by increased levels of
α-SMA [18]. Our previous data examining the global
gene expression patterns of DD-derived fibroblasts ver-
sus control carpal tunnel (CT)-derived fibroblasts con-
firms that there are numerous differences in their
transcriptomes even in in vitro culture, indicating a
stable intrinsically distinct disease physiology for DD-
cells [19, 20].Currently there is no treatment available that can suc-
cessfully cure, prevent progression or recurrence of DD.
In mild cases treatment is only observation, but as the
disease progresses needle fasciotomy or open surgery
becomes necessary to release contracture caused by the
fibrosis. Multiple surgical techniques have been de-
scribed for the treatment of DD that focus on resecting
the fibrotic tissue with the goal of improving finger
extension, but none have proven to be consistently
more effective than others [21]. Recently, direct injec-
tion of Clostridium histolyticum collagenase (CHC)
capable of lysing DD cords has been used with some
promise, although long term follow-up of these patients
reveals some significant complications that may neces-
sitate careful evaluation [22–24]. Alternative treatment
options, including nonsurgical molecular therapies to
halt the progression and recurrence of DD, would be a
welcome advance.
The development of such therapies has been slowed in
part by the lack of a well-described animal model in
which they may be initially assessed, as DD is a condi-
tion unique to humans, without counterpart in the
animal kingdom. We therefore investigated the charac-
teristics of human DD fibroblasts transplanted into an
immunodeficient animal host to see if they could main-
tain their distinct disease phenotype compared to con-
trol cells harvested from fascia from patients undergoing
carpal tunnel release. We monitored their persistence
over time and examined their molecular and histologic
profiles at the end of some two months after their ortho-
topic transplantation into nude rat forepaw.
Methods
Clinical specimens and primary cell culture
Dupuytren’s disease (DD) cord and carpal tunnel (CT)
fascial tissue samples were surgically resected at the
Division of Upper Extremity Surgery, Department of
Orthopaedic Surgery, Allegheny General Hospital,
Pittsburgh, PA. All subjects provided written informed
consent and specimens were collected with the
approval of the Allegheny-Singer Research Institute’s
Institutional Review Board (IRB protocol RC-4040)
involving human subjects. The study protocol con-
formed to the ethical guidelines of the1975 Declaration
of Helsinki.
Primary cultures of fibroblasts were isolated from
freshly resected DD cord tissue and normal palmar
fascia (CT cells) as previously described [25]. The
cultures were maintained in α-MEM medium supple-
mented with 10 % fetal bovine serum (FBS, Invitrogen™,
Life Technologies, Grand Island, NY) and 1 % antibiotic-
antimycotic solution (Sigma-Aldrich, St Louis, MO).
Cultures were maintained until a maximum of six pas-
sages, during which no change in the cell morphology was
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in vitro and transplantation experiments. While in culture,
fibroblasts were tagged in vitro with fluorescent Lipophilic
Cell Tracer Vybrant™ DiR (D12731; Invitrogen™, Life
Technologies) as per the manufacturer’s instructions. DiR
is a dialkylcarbocyanine dye with excitation and emission
maxima in the near infrared fluorescence region and this
high wavelength prevents conflation with any autofluores-
cence of tissue.
The CellTiter 96® non-radioactive cell proliferation assay
Cell proliferation/viability was examined using the
CellTiter 96® Non-Radioactive Cell Proliferation Assay
kit from Promega Corporation (Madison, WI). This
assay is based on the cellular conversion of a tetrazo-
lium salt into a formazan product that is easily de-
tected using a 96-well plate reader. Cells were plated
in 24-well plates at a density of 5x104 cells/well, grown
for 24 h, and then treated with DiR (10 μg/ml) for
30 min and/or for 24 h. After the exposure periods,
the cells were photographed and replaced with fresh
medium to perform the assay. Dye solution (20 μl) was
added and was incubated at 37 °C for an additional 2 h.
As a final step 133 μl solubilization/stop solution was
added and incubated at 37 °C for 1.5 h. Results were
obtained by measuring absorption at 570 nm by aliquoting
100 μl into a Corning 96 well flat transparent plate.
Nude rats
All studies on “nude” (rnu/rnu athymic) rats were per-
formed with approval by the Institutional Animal Care
and Use Committee (IACUC) of the Allegheny General
Hospital. The outbred nude rats were commercially pur-
chased from Charles River Laboratories (Wilmington,
MA). All animals were male, weighed between 250 and
350 g, and were acclimatized for 2 weeks prior to ex-
periments. Animals were housed in pathogen-free indi-
vidual cages.
Animal experiments
Male athymic rats (n = 6) were anesthetized with an in-
traperitoneal injection containing a loading dose of keta-
mine at 50 mg/kg and xylazine at 5 mg/kg. Fibroblasts
(1x107) derived from both DD-cord and CT tissues
labeled with DiR were transplanted subcutaneously using
a tuberculin syringe into the forepaws of the nude rats.
In each animal, the right forepaw was implanted with
CT-derived fibroblasts and the left forepaw received
DD-cord derived fibroblasts. All animals underwent IVIS
imaging of their forepaws at regular intervals by placing
the animal in a light-tight chamber, and images were
generated over a 10 s exposure using a cryogenically
cooled charge-coupled camera (IVIS Lumina II, Caliper
Life Sciences, Hopkinton, MA) to quantify photonsemitted by the animal. Animals were anesthetized with
inhaled 2 % isoflurane for imaging using a nose cone de-
livery device. The IVIS camera was maintained at stand-
ard settings, as follows: imaging mode fluorescent,
exposure time 10 s, and binning high with field of view
high. The visual output represents the number of pho-
tons emitted/cm2 as a pseudocolor image where the
maximum is red and minimum is purple. Once com-
piled, images were quantified for detection of fluores-
cent signal emitted from the forepaw using Xenogen
Living Image® software.
At 62 days post transplantation, animals were sacri-
ficed and the left and right rat forepaw tissues were
collected separately for further histological and real time
RT-PCR analyses. In harvesting the specimens with 3.5x
loupe magnification, the overlying rat skin was dissected
away from subjacent structures and retained as a
control. The remaining forepaw tissues, from the carpus
to the base of the digits, were harvested en bloc up in-
cluding immediately subcutaneous tissues down to bone
so as to minimize variability in tissue sampling. The
collected tissues from all the six animals were divided
for histology and real time RT-PCR analysis.
Histology
Rat forepaw tissues from both DD- and CT-injected ani-
mals, as well as control uninjected animals, were har-
vested at 62 days post transplantation and fixed in 10 %
neutral buffered formalin for histological evaluation.
Tissue samples embedded in paraffin were sectioned at a
thickness of 5 μm and the sections were simultaneously
stained with Masson’s trichrome to evaluate collagen
deposition following standard protocols.
RNA extraction
Tissues harvested from the rat forepaws were stored im-
mediately in RNAlater® (Ambion, Austin, TX). Total
RNA was extracted using the RNeasy Mini Kit (Qiagen
Inc., Valencia, CA) following manufacturer’s protocol
after homogenization using a homogenizer. The quality
and quantity of total RNA obtained were determined by
measuring the OD 260/OD 280 ratio using an ND-
1000 spectrophotometer (Nanodrop Technologies
Inc., Wilmington, DE) and by capillary electrophoresis
with the Agilent 2100 BioAnalyzer (Agilent Technologies
Inc., Palo Alto, CA) and a Nano6000 RNA chip, with all
sample RNA values >7.0.
Quantitative real time RT-PCR (qRT-PCR)
qRT-PCR was performed using kits obtained from
Applied Biosystems® Life Technologies (Grand Island,
NY) utilizing FAM™Taqman®MGB probes and a Taqman®
Universal PCR master Mix. Probes were used for three
gene products, namely human Type I collagen, human
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Fig. 1 Lipophilic cell tracer DiR® does not affect fibroblast proliferative
capacity. Cell viability and proliferative capacity of Vybrant DiR® labeled
and unlabeled CT- and DD-derived fibroblasts was compared in vitro.
No significant difference was observed in viability or proliferative
capacity between the labeled and unlabeled cell populations for
both CT- and DD-cells at either 30 min or 24 h. Studies were performed
on four independent cultures obtained from each of the cell types; values
are mean± SEM of two separate experiments performed in triplicate
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(α-SMA). Human GAPDH was used as the endogenous
normalization control for these studies. Reverse tran-
scription was performed using 100 ng/μl of total RNA
and with M-MLV-reverse transcriptase (Invitrogen™
Life Technologies). Subsequent PCR amplification and
detection of template was carried out using Applied
Biosystems transcript-specific assays including: type I
collagen (COL1A2) assay (ID-Hs 01028971_m1), type
III collagen (COL3A1) assay (ID-Hs 00947393_g1) and
α-SMA assay (ID-Hs 00426835_g1) using 15 ng/μl of
cDNA and 20X final concentration of Gene Expression
Mix which contains both forward and reverse primers
along with the gene-specific probes adjusted to a final
volume of 15.0 μl. The reaction set up and the thermal
cycling protocol was as previously described [19, 20].
Using the comparative critical cycle (Ct) and by relative
quantification methods (RQ), the expression levels of
the target genes were normalized to the GAPDH
endogenous control (ID-HS99999905_m1) and the rela-
tive abundance was calculated. Data were analyzed
using the 7900 HTSDS software version 2.1 provided
by Applied Biosystems.
Statistical analyses
Statistical analyses were performed using Student’s t test
function using Microsoft Excel program for qRT-PCR
analyses. p < 0.05 was considered statistically significant.
Repeated measures one-way ANOVA was used to deter-
mine the statistical significance for the data collected
using IVIS imaging. This was accomplished utilizing
GraphPad Prism 6.
Results
Labelling of DD and CT cells with DiR dye had no effect
on cell viability or proliferation
In order to track our populations of cells over time in
situ in the forepaw, we first labelled them with Vybrant™
DiR, a lipophilic dye that is only weakly fluorescent in
aqueous solution but is strongly fluorescent and photo-
stable when present in cell membranes. DiR uniformly
and effectively labeled both DD and CT cells, with no
light detected in the unlabeled cell population and with
no apparent distortion in cell morphology [26]. We
further confirmed that DiR did not have any significant
effect on the proliferative capacity of either DD or CT
cells, nor did it elicit any cytotoxic effect when com-
pared to unlabeled cell populations (Fig. 1).
DD- and CT-derived fibroblasts successfully persisted in
the forepaw of nude rats
We had previously demonstrated that administration of
both 1.0x107 and 1.5x107 DD-derived fibroblasts in
nude rat forepaws yielded successful persistence of cellsover ~8 weeks as evidenced by continued detection of
fluorescent signal emitted from the forepaw [26]. In
this study we investigated differences in the survival
ability between control (CT-derived fibroblasts) and
diseased (DD-derived fibroblasts) samples. CT- and DD
-derived fibroblasts were injected into the right and left
forepaws of nude rats respectively which were then im-
aged at regular intervals. Both CT- and DD-derived
cells survived in the forepaws over almost 9 weeks
(Fig. 2a). Quantitative assessment of emitted fluores-
cent signal over time was calculated, with day 5 set at
100 % of total flux. The amount of fluorescent signal
did show some decline over time in both populations,
but DD-derived cells showed significantly less decline
(therefore greater persistence) at day 62, retaining
almost 80 % of their original signal intensity compared
to less than 50 % for CT-derived cells (Fig. 2b). There
was no visual evidence of any significant migration of
the cell populations outside the forepaw zone.Masson’s trichrome staining showed increased collagen
deposition in the forepaw that received
DD- derived fibroblasts
One of the parameters used to determine the degree of
fibrosis is the amount of collagen deposited. Tissue
specimens obtained from forepaw injected with CT- and
DD-derived fibroblasts as well as untreated fascial con-
trol tissues were stained simultaneously with Masson’s
trichrome to determine the pattern of collagen depos-
ition; representative images are shown in Fig. 3. The
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Fig. 2 Imaging of human fibroblasts transplanted to nude rat forepaws shows cellular persistence for 62 days. Non-invasive in vivo imaging of the
forepaws receiving DiR labeled CT-and DD-derived fibroblasts showed persistence of both populations of cells to 62 days (n = 6). The emitted
fluorescent signal gradually declined over time for both cell types, but at day 62 DD-cells showed a significantly greater presence than CT-cells.
(a) A representative image of the emitted fluorescent signals over time. Animals were injected with DD-derived fibroblasts in the left forepaw and
with CT-derived fibroblasts on the right forepaw. (b) Quantitative assessment of emitted fluorescent signal over time, with day 5 set at 100 % of
total flux. Statistical analyses using ANOVA showed a significant difference in the intensity of persisting fluorescence signal over time between the
forepaw that received CT- and DD-derived fibroblasts. p value was < 0.0001
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Fig. 3 Histologic evaluation of fascial tissues injected with DD-derived
fibroblasts shows increased collagen deposition. A representative
histochemical Masson’s trichrome stain of forepaw tissues harvested
from three animals obtained from (a) untreated forepaw (b) forepaw
implanted with CT-derived fibroblasts and (c) forepaw implanted with
DD- derived fibroblasts is shown in x20 magnification. Tissues harboring
DD-cells showed markedly darker blue staining, signifying increased
collagen deposition
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injected forepaw showed consistently and appreciably
darker staining (Fig. 3c) when compared to the forepaw
that received CT-derived fibroblasts (Fig. 3b) and the
control forepaw (Fig. 3a); no consistent difference was
appreciated between CT-transplanted forepaws and na-
tive control fascia. This clearly indicates a denser depos-
ition of connective tissue (mainly collagen) within the
palmar fascia of the DD-derived fibroblasts, an indica-
tion that greater fibrosis is occurring.DD-derived fibroblasts showed persistently elevated
expression of multiple genes involved in fibrosis and
contraction after transfer to the forepaw
We next sought to determine if the differential physi-
ology between CT- and DD-derived fibroblasts seen in
in vitro culture, presumably reflective of their distinct
fibroproliferative capacities, would persist after trans-
plantation into the nude rat forepaw. We therefore used
qRT-PCR to examine the expression profiles of three
genes known to be significantly over-expressed in DD
physiology, specifically the Type I and Type III collagens,
as well as α-SMA. We compared CT-injected forepaws
to DD-injected forepaws, and also compared the pat-
terns of expression of these genes after 62 days in fore-
paws to their expression patterns in baseline cultured
CT- and DD-fibroblasts. We also examined the overlying
rat forepaw skin (in which no human cellular material
would be expected; although rat fascia may be a more
ideal control substrate, skin is also known to express
collagen and α-SMA in abundance).
Quantitative real-time RT-PCR expression analyses of
α-SMA, type I and type III collagen are shown in Fig. 4.
No expression at all was detected for any of the three
genes in rat skin, confirming the human-specificity of
the assays. Cultured DD-cells showed markedly higher
levels of all three genes than cultured CT-cells, as ex-
pected. These patterns generally persisted after trans-
plantation into the forepaw, and were amplified in some
instances. DD-cells in the forepaw continued to express
over twice as much α-SMA as CT-cells (Fig. 4a). DD-
cells in the forepaw similarly expressed much more Type
I collagen than CT-cells, and indeed showed an apparent
increase over even their baseline expression when main-
tained in culture (Fig. 4b). Both DD- and CT-cells
showed an apparent increase in Type III collagen ex-
pression than their baseline levels in culture, but here
again DD-cells in the forepaw showed significantly
higher levels than CT-cells in the forepaw (Fig. 4c). In
total, DD-cells, after 62 days in the forepaw, continued
to demonstrate significantly increased expression of each
of these markers of fibrosis than similarly transplanted
CT-cells.
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Fig. 4 (See legend on next page.)
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Fig. 4 Quantitative RT-PCR of transplanted forepaw tissues shows persistently increased expression of fibrosis genes in DD-cells versus CT-cells.
Real time qRT-PCR was performed to measure the mRNA expression levels of α-SMA (a), type I collagen (b) and type III collagen (c), all of which
were markedly elevated in DD-cells compared to CT-cells. For quantitative analysis of gene expression, the comparative threshold cycle (Ct)
method for relative quantification was used. The expression of the target genes was normalized to GAPDH expression. Values represent the
mean ± SEM of two separate experiments performed on RNA derived from the forepaw tissues of four animals, each performed in triplicate.
Parallel in vitro cultures of the CT- and DD-derived fibroblasts transplanted in vivo were used as controls. P value less than 0.05 was considered
as statistically significant
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A major factor hindering the development of novel
therapies for DD is the lack of a well-established in vivo
animal model to study the progression and recurrence
of the disease. Although there have been multiple pre-
vious attempts to develop such a model, these have all
been marked with certain features that have limited
their utility. As a first attempt Larsen et al. (1960) [27]
reported Dupuytren’s-like lesions in monkeys after
traumatic disruption of palmar fascial fibers. Although
this model was situated in the appropriate anatomical
location, there is no underlying Dupuytren’s cell type
involved, and this model may be better regarded as one
of post-traumatic fibrosis rather than of a distinct fibro-
proliferative disorder such as Dupuytren’s.
Subsequent models have used explanted human
Dupuytren’s tissue as the basis for their pathology, but
have introduced them into heterotopic locations in the
animal hosts. Kischer et al. (1989) [28] determined that
DD tissues implanted into subcutaneous pockets in the
suprascapular area of nude mice maintained their histo-
logic character and electron microscopic structure.
Although the size of implants reduced in size over time,
the appearance of fibroblasts and the spatial pattern of
collagen remain unchanged. The authors concluded that
the use of implants into nude mice maybe useful for fur-
ther experimental studies of DD but to date there have
been no follow up studies with this model. Kuhn et al.
(2001) [29] used a vascularized sandwich flap model in
the abdominal skin of nude rats to maintain viable DD-
affected palmar fascia tissue explants for up to 60 days.
The authors also demonstrated that perfusion of the
explanted DD tissue by TGFβ2 upregulated collagen I
and III, and that perfusion with antibody against TGFβ2
prevented the same increase. Both of these studies used
immunodeficient hosts in a manner similar to this in-
vestigation, but used whole tissues rather than focusing
on a specific cell type (fibroblasts/myofibroblasts) and
placed them into an aphysiological milieu rather than
the orthotopic location of the palmar fascia.
Recently, Karkampouna et al. (2014) [30] have re-
ported an ex vivo “clinical trial” system by culturing DD
specimens after surgical removal, observing that the
tissue so cultured preserved the pathological status of
the disease by maintaining the complex organization ofthe ECM and its three-dimensional (3D) structure. The
authors also demonstrated that targeting TGFβ1 re-
ceptor expression in cultured DD specimens by anti-
sense oligonucleotide-mediated exon skipping showed
a specific reduction in fibrotic proteins and caused a re-
versal of the fibrotic phenotype. This is an encouraging
result, but their system extends for only seven days in
culture with treatments administered over three days
time. It remains to be seen whether it can be adapted
to the longer time periods over which DD manifests,
and it may not fully capture all factors in play when
evaluating in vivo disease progression and recurrence.
In our effort to develop an animal model of DD we
have previously utilized athymic “nude” rats and have
showed that DD-derived fibroblasts can persist in the
forepaw of the animals for up to 8 weeks, retaining their
myofibroblast phenotype [26]. In the present study, we
demonstrate that DD cells show greater persistence over
time than control CT cells, and retain a distinctly pro-
fibrotic physiology. While we did see molecular and
histologic evidence of building fibrosis with DD cells, we
did not see the development of a frank tissue contrac-
ture analogous to the clinical presentation in humans.
This may be because our model incompletely mimics
the human pathophysiology, or it may be that more time
is required for that degree of fibrosis and contracture to
manifest. Dupuytren’s is after all a disease with a slow
and progressive onset, often taking years to become clin-
ically significant, and for practical reasons our studies
here only extend to nine weeks, a relatively lengthy ex-
perimental period but still short compared to the clinical
condition. Ongoing studies to allow these cells to persist
in situ for even longer periods of time may help to
clarify these possibilities. Because even DD cells do show
some element of decline over time, it may even become
necessary to administer repeated doses of DD cells to
achieve frank tissue contracture.
But in some senses this may not be necessary. The
model we describe here for the first time places the
principal effector cells of DD in the physiologically rele-
vant orthotopic anatomical location, and follows their
behavior over time. The increased evidence of fibrosis
we see with DD cells compared to CT cells suggests
that a meaningful recapitulation of DD physiology is
occurring, and can already serve as a baseline against
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Any agent found to diminish the DD-dependent fibrotic
characteristics seen thus far may be regarded as a po-
tential candidate for clinical translation. An advantage
of this model in that regard is that any therapy to be
examined must first be made accessible to the DD cells
in the subcutaneous/palmar fascial tissues, overcoming
the skin barrier even as it would have to be in an actual
clinical application. This might be accomplished by
subcutaneous injection (as the cells themselves were
injected), or agents manufactured to penetrate the skin
barrier could be evaluated after topical administration.
We hope that further refinements of this model and its
use in testing new molecular therapies can help to
accelerate improvements in the care of patients with
Dupuytren’s disease.
Conclusions
For the first time this study describes an animal model
for Dupuytren’s disease at the orthotopic anatomical
location. We also show that gene expression differences
between control (CT-derived) and diseased (DD-derived)
fibroblasts persist when these cells are transplanted to
the forepaw of the nude rat. These preliminary findings
indicate that, with further refinements, this animal
model holds promise as a baseline for investigating novel
therapeutic regimens to determine an effective strategy
in treating DD.
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